Vyndaqel (tafamidis) vs Wainua (eplontersen)

Vyndaqel (tafamidis) is approved for the treatment of transthyretin-mediated amyloidosis (ATTR) in adults to reduce cardiovascular mortality and related hospitalizations, functioning by stabilizing the transthyretin protein to slow the progression of the disease. Wainua (eplontersen), on the other hand, is an investigational antisense oligonucleotide designed to reduce the production of transthyretin protein, potentially treating ATTR with polyneuropathy or cardiomyopathy, though its approval status and efficacy are subject to the results of ongoing clinical trials. When deciding between these medications, it is important to consider the specific type of ATTR, the stage of the disease, the safety and efficacy data of the approved medication (Vyndaqel), and the individual patient's medical history, while also consulting with a healthcare provider for the most current treatment options and clinical trial availabilities.

Difference between Vyndaqel and Wainua

Metric	Vyndaqel (tafamidis)	Wainua (eplontersen)
Generic name	Tafamidis	Eplontersen
Indications	Treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults	Treatment of hereditary transthyretin-mediated amyloidosis
Mechanism of action	Stabilizes transthyretin tetramer, preventing misfolding and amyloidogenesis	Antisense oligonucleotide that binds to transthyretin (TTR) mRNA, resulting in its degradation and reduced serum and tissue TTR protein levels
Brand names	Vyndaqel	Wainua
Administrative route	Oral	Subcutaneous
Side effects	Urinary tract infection, vaginal infection, diarrhea, pain in extremity	Injection site reactions, nausea, headache, fatigue
Contraindications	Known hypersensitivity to tafamidis or any component of the formulation	Not provided
Drug class	Transthyretin stabilizer	Antisense oligonucleotide
Manufacturer	Pfizer	Ionis Pharmaceuticals

Efficacy

Vyndaqel (Tafamidis) and Its Efficacy in Treating Amyloidosis

Vyndaqel (tafamidis) is a medication approved for the treatment of transthyretin amyloidosis (ATTR), a rare condition characterized by the accumulation of abnormal amyloid proteins in the body's tissues and organs. Tafamidis works by stabilizing the transthyretin protein, preventing its misfolding and subsequent buildup as amyloid fibrils. Clinical trials have demonstrated the efficacy of Vyndaqel in patients with hereditary transthyretin amyloidosis (hATTR) with polyneuropathy. The use of tafamidis has been shown to significantly reduce the progression of neurologic impairment and to improve quality of life for patients suffering from this condition.

In addition to its effects on neuropathy, Vyndaqel has also been evaluated for its efficacy in treating cardiomyopathy associated with ATTR. Studies have indicated that tafamidis can lead to a reduction in hospitalizations related to cardiovascular issues and can decrease mortality in patients with ATTR cardiomyopathy. By stabilizing the transthyretin tetramer, tafamidis helps to slow the deterioration of heart function, providing a therapeutic option for patients with this life-threatening manifestation of amyloidosis.

Wainua (Eplontersen) and Its Role in Amyloidosis Treatment

Wainua (eplontersen), formerly known as IONIS-TTR-LRx, is an investigational antisense oligonucleotide designed to reduce the production of transthyretin (TTR) protein by the liver. It is being studied for the treatment of ATTR amyloidosis, including both the hereditary form and the wild-type form that usually affects the heart. Eplontersen works by binding to the TTR mRNA, promoting its degradation, and thereby decreasing the production of TTR protein and the subsequent formation of amyloid fibrils.

Although still under investigation, preliminary data from clinical trials suggest that eplontersen can significantly lower TTR protein levels in patients with ATTR amyloidosis. The reduction in TTR levels is expected to translate into clinical benefits, such as slowing the progression of neuropathy and cardiomyopathy. Ongoing studies are aimed at further evaluating the long-term efficacy and safety of eplontersen in patients with ATTR amyloidosis, with the goal of providing a new treatment option that targets the underlying cause of the disease.

Regulatory Agency Approvals

Vyndaqel

European Medical Agency (EMA), European Union
Food and Drug Administration (FDA), USA
Health Canada
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Therapeutic Goods Administration (TGA), Australia

Wainua

Food and Drug Administration (FDA), USA

Access Vyndaqel or Wainua today

If Vyndaqel or Wainua are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.

Buy Vyndaqel

Buy Wainua

How it works

Make an enquiry

Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.

Breeze through the paperwork

We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.

Get a personalized quote

We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.

Receive your medicine

Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.

Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.

Let's talk

If you have any questions, call us or send us a message through WhatsApp or email: